• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deal search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • Q&A
    • Videos
    • Comment
    • Analysis
    • People moves
    • In Profile
  •  
    Analysis
    • Videos
    • Q&A
    • Comment
    • In Profile
    • Podcast
    • Fundraising
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
      • Deals search
      • Exits search
      • Funds search
      • Sponsors search
      • Advisers search
      • LPs search
      • League tables
      • Reports
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
UNQUOTE
  • Exits

Progressio, Idea Capital reap €130m in Italchimici trade sale

  • Amedeo Goria
  • Amedeo Goria
  • 02 June 2016
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

Private equity backers Progressio and Idea Capital Funds have wholly divested Italian pharmaceutical company Italchimici to listed corporate Recordati for €130m.

According to a statement, the all-equity deal saw the company valued at €130m. As part of the deal, Progressio sold its 71.9% stake in the business, while Idea Capital exited its 26.8% stake. Italchimici's management team also sold its 1.3% stake in the business. Investors reaped a 3x money multiple.

According to a source familiar with the situation, the GPs received several acquisition offers from larger corporates a few months after the acquisition of Italchimici in 2015. Subsequently, the shareholders initiated an off-market purchase process with two industrials, with Recordati winning the final bid.

Speaking to unquote", the source said Progressio's 2009-vintage vehicle, Progressio Investimenti II, has now invested 80% of its committed capital and the GP plans to make one final investment this year. Moreover, the private equity manager is eyeing the launch of its third fund, Progressio Investimenti III, which will have the same strategy as its predecessors.

Previous funding
Italian GPs Progressio and Idea Capital backed the company's MBO in July 2015. Progressio acquired a majority stake in the business through its Progressio Investimenti II fund, while Idea Capital acquired a minority stake with its vehicle Idea Efficienza Energetica e Sviluppo Sostenibile.

Company
Founded in 1960 and headquartered in Milan, Italchimici produces drugs and medical devices for the pharmaceutical sector. Its flagship products include Reuflor, Peridon and Aircort and focus on the gastroenterology and respiratory diseases segments.

The business generated €46m of revenues and €11m of EBITDA in 2015.

People
Progressio – Filippo Gaggini (CEO); Alessandro Petraccia (investment manager); Beatrice Capretti (associate).
Idea Capital Funds – Sergio Buonanno (managing director).
Italchimici – Riccardo Zagaria (CEO).
Recordati – Giovanni Recordati (chair, CEO).

Advisers
Equity – Lombardi Molinari & Associati (legal).
Buyer – Studio Bonelli Erede e Pappalardo (legal).

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Exits
  • Healthcare
  • Southern Europe
  • Italy
  • Progressio SGR
  • DeA Capital
  • Trade sale

More on Exits

Partners Group to release IMs for Civica sale in mid-September
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • Exits
  • 04 September 2023
Actera Group explores strategic options for Celebi Ground Handling
Actera Group explores strategic options for Celebi Ground Handling

Several investors placed bids for the company in 2022 but mismatch in pricing didn't lead to a deal

  • Exits
  • 30 August 2023
Norstat owner Triton Partners explores sale via William Blair
Norstat owner Triton Partners explores sale via William Blair

GP has owned the Norway-headquarterd market research business for almost four years

  • Exits
  • 25 August 2023
IK Investment-backed Eres expected to hit the auction block by 2024
IK Investment-backed Eres expected to hit the auction block by 2024

French employee savings distribution and management firm could be valued at a few hundred million euros

  • Exits
  • 24 August 2023

Latest News

Partners Group to release IMs for Civica sale in mid-September
  • Exits
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
BHM Group builds on PE strategy, eyes European medtech and renewable energy acquisitions
  • Investments
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Czech Republic-headquartered family office is targeting DACH and CEE region deals

  • 01 September 2023
Redalpine expands leadership team amid CHF 1bn-plus fundraise
  • Venture
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO

  • 31 August 2023
Change Ventures aims to hold final close for EUR 20m third fund by mid-2024
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds

  • 31 August 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013